Result of Bortezomib Induction Therapy Prior to Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma Cases in Mongolia
DOI:
https://doi.org/10.24079/cajms.2017.06.011Keywords:
Stem Cell, Transplantation, Bortezomib, Multiple MyelomaAbstract
Objectives: For last 5 years, we have focused on establishing autologous stem cell transplantation (ASCT) in Mongolia. Herein, we report on three Mongolian multiple myeloma (MM) cases treated with bortezomib and dexamethasone (VD) prior to ASCT. Methods: The MM diagnosis was confirmed by bone marrow aspiration, urine protein electrophoresis, and serum protein electrophoresis. Results: Circulating white blood cells appeared 8-10 days after ASCT. Platelet levels recovered 10 -15 days after ASCT. Conclusion: In our MM cases, the VD regimen prior to ASCT obtained good response rates without the impairment of stem cells.
Downloads
40
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Mongolian National University of Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.